Smith & Nephew SNATS (NYSE:SNN) Stock Price Breaks Above 200 Day Moving Average – Should You Sell?

Smith & Nephew SNATS, Inc. (NYSE:SNN) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $31.06 and traded as high as $32.66. Smith & Nephew SNATS shares last traded at $32.4660, with a volume of 2,679,835 shares.

Wall Street Analyst Weigh In

SNN has been the topic of several research reports. Morgan Stanley lowered shares of Smith & Nephew SNATS from an “overweight” rating to an “equal weight” rating in a report on Wednesday, September 2nd. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a report on Sunday, September 13th. Barclays cut shares of Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, August 5th. Bank of America downgraded Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a research report on Tuesday, September 8th. Finally, BTIG Research began coverage on Smith & Nephew SNATS in a research note on Monday, August 31st. They set a “neutral” rating on the stock. One analyst has rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Smith & Nephew SNATS currently has a consensus rating of “Hold” and a consensus target price of $31.91.

Smith & Nephew SNATS Stock Performance

The business has a fifty day moving average of $28.41 and a 200-day moving average of $31.06. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14.

Institutional Trading of Smith & Nephew SNATS

Several institutional investors and hedge funds have recently modified their holdings of the business. Ethic Inc. boosted its holdings in shares of Smith & Nephew SNATS by 10.5% during the third quarter. Ethic Inc. now owns 29,168 shares of the medical equipment provider’s stock worth $786,000 after purchasing an additional 2,762 shares during the period. Alps Advisors Inc. lifted its stake in Smith & Nephew SNATS by 4.3% in the third quarter. Alps Advisors Inc. now owns 25,790 shares of the medical equipment provider’s stock worth $695,000 after acquiring an additional 1,054 shares during the period. Ashton Thomas Private Wealth LLC boosted its holdings in Smith & Nephew SNATS by 15.4% in the third quarter. Ashton Thomas Private Wealth LLC now owns 10,676 shares of the medical equipment provider’s stock valued at $288,000 after acquiring an additional 1,427 shares in the last quarter. Trek Financial LLC boosted its holdings in Smith & Nephew SNATS by 14.6% in the third quarter. Trek Financial LLC now owns 9,721 shares of the medical equipment provider’s stock valued at $262,000 after acquiring an additional 1,241 shares in the last quarter. Finally, Vise Technologies Inc. lifted its position in shares of Smith & Nephew SNATS by 8.6% in the 3rd quarter. Vise Technologies Inc. now owns 17,847 shares of the medical equipment provider’s stock worth $481,000 after purchasing an additional 1,409 shares during the period. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company that develops and manufactures products used by healthcare professionals to treat injuries, manage wounds and restore patients’ mobility. Founded in 1856 by Thomas James Smith in Hull, England, the company has grown from a pharmacy business into an international healthcare manufacturer.

The company operates across three principal areas: orthopaedics, sports medicine and ear, nose and throat (ENT), and advanced wound management.